LRRC8A and breast carcinoma: This suggests that the high expression of SLAMF1, SLAMF7, CD48, and IGLL1, as well as the low expression of LRRC8A, may induce or participate in activating the immune response within breast cancer tissue, regulating the activity and quantity of immune cells, thereby influencing the recognition and attack of tumor cells by immune cells.